Seliciclib is an inhibitor of Cdk 2, 7 and 9, which has been shown to induce tumor shrinkage as well as induce tumor apoptosis, reduced expression of Mcl-1, cyclin D1 and pRB in paired tumor biopsies obtained following around 8 days of treatment3,9. This evidence concerns the gene RB1 and neoplasm.